about
New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticlesThe development of atypical hemolytic uremic syndrome depends on complement C5Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.Dynamics of complement activation in aHUS and how to monitor eculizumab therapyPrevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.Phage display technology for human monoclonal antibodies.A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome.Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.Complement as effector system in cancer immunotherapy.Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers.Complement in human diseases: Lessons from complement deficiencies.Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.Humoral immunotherapy of multiple myeloma: perspectives and perplexities.Meniscal Ossicles as micro-CT Imaging Biomarker in a Rodent Model of Antigen-Induced Arthritis: a Synchrotron-Based X-ray Pilot StudyPotential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia.P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating.Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosisExploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.Cubosomes for in vivo fluorescence lifetime imaging.Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.Simple scale-up of recombinant antibody production using an UCOE containing vector.NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of RituximabComplement C1q and C8 deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illnessSelective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in ratsIn vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imagingC7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory functionTreatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgeryThe Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target
P50
Q27306995-61D2467B-81A6-4C83-863D-2897D2AD4CBDQ28300378-A0F3DC11-4FDA-4A64-AC93-2EFFD7BCBF1FQ33217628-4F9E8699-1A26-46DC-9AAE-2BB5DE71CA23Q33416519-465523D3-A697-45D9-9E88-82338F084832Q34625994-1115F9FB-203E-48E9-B956-310809C15373Q34987657-C0B676DF-5E4F-4990-855C-A60DA98CBE86Q35124036-5921B61A-DDAA-4CD6-8854-7CA039EE4979Q35787096-C7EB286D-7961-4703-8CAE-16C873A9B452Q36850681-4D2E4996-BB1A-462D-AB29-6DA2EBCC7021Q36923241-0DBD91DB-B782-4618-BF6D-C7D4A87A6D3DQ37501005-C9F5B38C-AA3E-4D65-B3FE-2F9559561E7DQ37709461-A35C1F99-98BC-4D3B-8604-BC5093EA1257Q37724368-38215881-AD7F-4595-8C82-AF71E10221F7Q38633174-168791E3-D04C-4EAE-B19F-B3AC47D61CF4Q38945688-38CC97F5-E035-48EC-9F68-088A7EEC5F89Q39840898-4246BB0F-576C-4A45-85A1-BEAA50B72F6CQ40296292-F3D0AB91-D1AD-4419-9AC5-D7CC4D7558D0Q40329074-263B191B-7CC9-4228-8368-1E66F0BE6953Q40672986-D184D443-55C1-448B-B0BD-3FD9720CC174Q41934808-1C88BD66-4DD2-450D-8B99-AE65D39FFD58Q50983422-F278E02E-B9A0-4895-B22D-978E424A9C0CQ51076481-C75B8C6A-F357-4476-A479-FA55845ECAC1Q51762269-E9841F40-063C-4D43-87A0-E8FB5C54D29DQ52931736-68A0EA69-63A7-428E-A8EF-A9A71AA41368Q57374767-E4F40042-1D74-4C8B-A678-CB2851C69F94Q61651859-42E5C2F9-D153-497C-9D2C-885ADA4B37BEQ80060096-55465D3C-C029-48BD-B651-799EB9248D00Q83148455-DCB1C085-BD72-49FF-B957-301D3A4934E4Q83264219-C8E12A2C-CEC4-449F-82BB-D8A4D864BCECQ83447337-7AF59862-D057-4D97-A2B5-6B8AA01DB708Q86868173-3B742300-807F-4466-A17D-127810D011EAQ90411487-0EC69F08-26CC-4E3E-97A4-A7ABAF1E2F51
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Macor
@ast
Paolo Macor
@en
Paolo Macor
@es
Paolo Macor
@nl
Paolo Macor
@sl
type
label
Paolo Macor
@ast
Paolo Macor
@en
Paolo Macor
@es
Paolo Macor
@nl
Paolo Macor
@sl
prefLabel
Paolo Macor
@ast
Paolo Macor
@en
Paolo Macor
@es
Paolo Macor
@nl
Paolo Macor
@sl
P106
P1153
6506723506
P21
P31
P496
0000-0003-3079-4019